NewsBenzingaALXオンコロジーホールディングスは、自然医学誌において、ASPEN-06無作為化第2相臨床試験の臨床データの公表を発表し、HER2陽性胃癌におけるエボラセプトの持続的な臨床効果を示す ALXオンコロジーホールディングスは、自然医学誌において、ASPEN-06無作為化第2相臨床試験の臨床データの公表を発表し、HER2陽性胃癌におけるエボラセプトの持続的な臨床効果を示す Benzinga 2026.09.28 12:03 (GMT+0) Open on Benzinga Other news BofA: US memory stock valuations show signs of cycle bottom, market concerns overblown ServiceNow, Eaton, SentinelOne And A Financial Stock: CNBC’s ‘Final Trades’ Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q3 Earnings Centrus Energy Acquires Westerman Holdings For ~$116M, Funded Through Combination Of ~$95M Cash On Hand And $21M Of Equity Curaleaf Cites Aurora Board's Fiduciary Duty Regarding Previously Recommended Shareholder Rejection Of Curaleaf's Enhanced Proposal Rekor Systems Files Verified Complaint In Delaware Chancery Court Against Former Director Viraj Mehta Alleging Breach Of Fiduciary Duty Of Loyalty In Connection With The Company’s December 2025 Financing
Centrus Energy Acquires Westerman Holdings For ~$116M, Funded Through Combination Of ~$95M Cash On Hand And $21M Of Equity
Curaleaf Cites Aurora Board's Fiduciary Duty Regarding Previously Recommended Shareholder Rejection Of Curaleaf's Enhanced Proposal
Rekor Systems Files Verified Complaint In Delaware Chancery Court Against Former Director Viraj Mehta Alleging Breach Of Fiduciary Duty Of Loyalty In Connection With The Company’s December 2025 Financing
